The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer.
about
Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceStructure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors.Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIsRandomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma.Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure.Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancerOncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology.Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance.Necitumumab for non-small cell lung cancer.The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer.microRNAs: An Emerging Paradigm in Lung Cancer Chemoresistance.miR-198 targets SHMT1 to inhibit cell proliferation and enhance cell apoptosis in lung adenocarcinoma.Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerSelection of Non-small Cell Lung Cancer Patients for Intercalated Chemotherapy and Tyrosine Kinase InhibitorsThe activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells.Design, Synthesis, and Evaluation of Ribose-Modified Anilinopyrimidine Derivatives as EGFR Tyrosine Kinase Inhibitors.Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction.miR-373-3p promotes lung adenocarcinoma cell proliferation via APP.AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis.Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor.
P2860
Q28079320-8CE571A5-DD92-426E-835F-4F1797E796BDQ33812445-454C6F90-EF2C-4AB6-9796-56953C68D556Q36319739-689D7FB1-3F9D-4423-BD4D-9A9AEC1DE369Q36478708-19A9FDB2-CB40-43AF-96C7-15D1AD3B9DC2Q36544438-F8FF3B98-65FF-4E54-8338-3F26534B0BD8Q36844350-BB59463B-DDBC-444A-A0BA-2EDB2D50E508Q37098321-9C2D1E01-CF10-4A08-972F-A5692D217A84Q37225463-B5B5F38A-91FF-4D4A-A75F-D59B70CB41E3Q37347236-89343178-28B1-4600-8385-A9226E9F50FFQ37357699-0D85EBC1-0955-4200-B4A0-E7659546A85BQ37580410-FA79FC4D-07DA-4E70-B87E-8D5419E27E55Q38504491-E328A7E8-D8FD-4BD3-B692-B1B92B2CDDCEQ38519582-99F8477B-A688-4F2D-9C6D-D2DABACB41FEQ38587521-77DA8AF5-4268-413B-ABC1-1E49B0EA600FQ38638204-6158BC46-8697-48FC-8F6D-A6EC49BE05E0Q38820622-1F18CB1A-92EB-4C41-89D5-2C3EAB211D38Q39646977-FA6FF39D-A03B-445A-966D-7ED2CBDD368EQ41678123-F27DD0C4-F19E-43E1-9168-487B9D1F27D7Q42378470-265DA06E-A89B-4EC4-8271-943B3E51D81EQ47095218-4E7E99EB-3333-42A7-A0C0-88255E51DBBCQ47162428-2E2C672A-82C6-4886-ACEB-4F1D4CB2E4EEQ50161575-2E070D2C-AD9E-40FD-9CA0-4DC3CCE85975Q51738393-575A2E58-237C-4D52-A6EC-77C39DF89880Q52653002-F602AD59-5F4E-4CED-B214-005C41FB296FQ52723939-82182C44-7557-4F71-82F3-DA5A880F78AC
P2860
The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
The next generation of epiderm ...... the treatment of lung cancer.
@en
type
label
The next generation of epiderm ...... the treatment of lung cancer.
@en
prefLabel
The next generation of epiderm ...... the treatment of lung cancer.
@en
P2093
P2860
P356
P1433
P1476
The next generation of epiderm ...... the treatment of lung cancer.
@en
P2093
Conor E Steuer
Fadlo R Khuri
Suresh S Ramalingam
P2860
P356
10.1002/CNCR.29139
P407
P577
2014-12-17T00:00:00Z